Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01040728 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT01040728 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 122 participants.
The verdict
NCT01040728, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.
Interventions
- DRUG Olodaterol (BI1744) Low
- DRUG Olodaterol (BI1744) High
- DRUG Tiotropium 18 mcg
- DRUG Placebo (for Olodaterol (BI1744)l)
- DRUG Placebo (for Tiotropium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01040728
The ClinicalTrials.gov registry entry for NCT01040728 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Olodaterol (BI1744) Low is the first listed.
NCT01040728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01040728 about?
NCT01040728 is a clinical study titled "A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease". The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatm...
What is the current status of trial NCT01040728?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2010-01.
What interventions are being tested in trial NCT01040728?
The interventions under investigation include: Olodaterol (BI1744) Low (DRUG), Olodaterol (BI1744) High (DRUG), Tiotropium 18 mcg (DRUG), Placebo (for Olodaterol (BI1744)l) (DRUG), Placebo (for Tiotropium) (DRUG).
Who is sponsoring clinical trial NCT01040728?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.